Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
IPO Year: 2018
Exchange: NASDAQ
Website: neurostar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2024 | Outperform → Mkt Perform | William Blair | |
| 10/14/2021 | $18.00 → $12.00 | Market Outperform | JMP Securities |
| 10/13/2021 | Outperform → Mkt Perform | William Blair | |
| 10/13/2021 | Buy → Neutral | BTIG |
3 - Neuronetics, Inc. (0001227636) (Issuer)
3 - Neuronetics, Inc. (0001227636) (Issuer)
3 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectivelyClosed acquisition of Greenbrook TMS effective as of December 9, 2024Expects full year 2025 pro forma year-over-year revenue growth of 12% - 19%Expects to realize over $22 million in annualized cost synergies Expects to achieve cash flow breakeven in the third quarter of 2025 MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company") today announced preliminary fourth quarter and full year 2024 revenue and issued 2025 financial guidance. Preliminary Fourth Quarter and Full Year 2024 Results
MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company") today announced the granting of inducement awards to a new employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company's Board of Directors and were made as material inducements to the recipients' employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan. Performance restricted stock units ("PRSUs") NameNumber of PRSUsVesti
MALVERN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company") today announced the granting of inducement awards to new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company's Board of Directors and were made as material inducements to the recipients' employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan. Performance restricted stock units ("PRSUs") NameNumber of PRSUsVestin
MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTC:GBNHF) ("Greenbrook", and together with Neuronetics, the "Combined Company") today announced that they have successfully completed the previously announced transaction whereby Neuronetics acquired all of the issued and outstanding common shares of Greenbrook (the "Greenbrook Shares") by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the "Arrangement"). Each Greenbrook Share outstanding immediately prior to the effective time of the Arrangement was exchanged for 0.01021 of a share of common stock of Neuronetics (
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast. A live audio webcast of the presentation will be available online at the investor relations page of the Company's website at ir.neuronetics.com. About Neuronetics Neuronetics, Inc. believes that mental health is as im
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ:STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say that the Company expects to achieve cash flow breakeven by the third quarter of 2025, not the second. The corrected release follows: Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and ope
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 13,500 shares of the Company's common stock (RSUs) to seven new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. Each of the RSU grants vests ratably in
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024. Third Quarter 2024 Highlights Third quarter 2024 revenue of $18.5 million, a 4% increase as compared to the third quarter 2023U.S. NeuroStar Advanced Therapy system revenue of $4.1 million in the quarter, representing 48 systemsU.S. treatment session revenue increased by 2% versus the third quarter of
MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/yk5bidgv. To listen to the conference call on your telephone, participants may register for
MALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the American Academy of Child and Adolescent Psychiatry (AACAP) in Seattle, WA, from October 14th-19th, including an oral presentation at the "Research Pipeline: New Findings on Therapeutics" session featuring data generated utilizing the NeuroStar TMS (transcranial magnetic stimulation) System. In addition, NeuroStar will exhibit at booth #416, where demonstrations of the device will be given. "We are
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4/A - Neuronetics, Inc. (0001227636) (Issuer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
8-K/A - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
10-Q - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
DEFA14A - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
SC 13D - Neuronetics, Inc. (0001227636) (Subject)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
SC 13G - Neuronetics, Inc. (0001227636) (Subject)
SC 13G - Neuronetics, Inc. (0001227636) (Subject)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
SC 13G - Neuronetics, Inc. (0001227636) (Subject)
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ:STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say that the Company expects to achieve cash flow breakeven by the third quarter of 2025, not the second. The corrected release follows: Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and ope
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024. Third Quarter 2024 Highlights Third quarter 2024 revenue of $18.5 million, a 4% increase as compared to the third quarter 2023U.S. NeuroStar Advanced Therapy system revenue of $4.1 million in the quarter, representing 48 systemsU.S. treatment session revenue increased by 2% versus the third quarter of
MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/yk5bidgv. To listen to the conference call on your telephone, participants may register for
MALVERN, Pa. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTC:GBNHF) ("Greenbrook") today announced that they have entered into a definitive arrangement agreement (the "Definitive Agreement") in which Neuronetics will acquire all of the outstanding common shares of Greenbrook in an all-stock transaction. "This transaction brings together two of the leaders in the mental health space in the U.S., which will allow us to provide access to innovative care to patients suffering from mental health conditions. Leveraging the significant scale and capabilities of the two businesses, we can drive increased awareness of Neur
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2024. Second Quarter 2024 Highlights Second quarter 2024 revenue of $16.5 million, a 7% decrease as compared to the second quarter 2023U.S. NeuroStar Advanced Therapy system revenue of $4 million in the quarter, representing 50 systemsU.S. treatment session revenue decreased by 5% ve
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2024 financial and operating results prior to market open on Monday, August 12th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/xsxbsaxh. To listen to the conference call on your telephone, participants may register f
MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights First quarter 2024 revenue of $17.4 million, a 12% increase as compared to the first quarter 2023U.S. treatment session revenue increased by 22% versus the first quarter of 2023U.S. NeuroStar Advanced Therapy system revenue of $3.3 million, in the quarter; the Company s
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/i3t5h9gs. To listen to the conference call on your telephone, participants may register for the
MALVERN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2023. Fourth Quarter 2023 Highlights Fourth quarter 2023 revenue of $20.3 million, a 12% increase as compared to the fourth quarter 2022U.S. NeuroStar Advanced Therapy system revenue of $4.5 million, in the quarter, the Company shipped 59 systemsAchieved record U.S. treatment session
MALVERN, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2023 financial and operating results prior to market open on Tuesday, March 5th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/7cha7jae. To listen to the conference call on your telephone, participants may register for
William Blair downgraded Neuronetics from Outperform to Mkt Perform
JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously
William Blair downgraded Neuronetics from Outperform to Mkt Perform
BTIG downgraded Neuronetics from Buy to Neutral
Piper Sandler reiterated coverage of Neuronetics with a rating of Overweight and set a new price target of $25.00 from $27.00 previously
William Blair upgraded Neuronetics from Market Perform to Outperform
Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja
MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023. "Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," said Rob Cascella, Chairman of the Board of Neuronetics. "His depth of experience with public companies and his passion for innovative medical technologies will
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management
MALVERN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Megan Rosengarten as a new member of its Board of Directors. Following her appointment, the Neuronetics' Board of Directors now has eight members."I am very pleased to have Megan join Neuronetics' Board of Directors," said Keith Sullivan, President and Chief Executive Officer of Neuronetics, Inc. "Her background in medical technology product development, marketing, and strategic communicatio
MALVERN, Pa., April 14, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Brian Farley will retire from the Neuronetics' Board of Directors and his role as Chairman following the company's Annual Meeting of Stockholders on May 27, 2021. Robert Cascella, who joined the Board of Directors on April 1, 2021, will be appointed as Chairman of its Board of Directors following Mr. Farley's retirement. Following Mr. Farley's retirement, the Board of Directors will have seven members. "
MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Robert A. Cascella to its Board of Directors, effective immediately. Following his appointment, the Neuronetics’ Board of Directors now has eight members. “I am very pleased to have a leader of Rob’s quality and experience join Neuronetics’ Board of Directors,” said Keith Sullivan, President and Chief Executive Officer of Neuronetics, Inc. “His history of value creation in healthcare uniq
MALVERN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Gregory Harper, the company’s Vice President, R&D and Clinical, will retire effective March 31, 2021. “I am grateful to Greg for his outstanding leadership of Neuronetics’ product development function over the past five years and more recently clinical affairs. Greg has made enormous contributions to our organization,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, Inc. “
MALVERN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the expansion of its commercial organization. Sales Organization UpdateAs part of the Company’s previously announced sales organization optimization initiative, the Company recently expanded the size of its sales organization, including the addition of: Thirteen new Business Development Managers (“BDMs”), bringing the total number of BDMs to 22Nine new NeuroStar Practice Consultants (“NPCs”), bringing the to